Nautilus Biotechnology Inc
NASDAQ: NAUT · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-09-11
Nautilus Biotechnology Inc (NAUT) Financial statements
SEC filings — annual and quarterly data.
Margin trends — annual
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2018 | — | $626.60M | — | — | — |
| 2019 | — | $-9.62M | — | — | — |
| 2020 | $0.00 | $-15.62M | — | — | — |
| 2021 | $0.00 | $-50.31M | — | — | — |
| 2022 | $0.00 | $-57.92M | — | — | — |
| 2023 | $0.00 | $-63.67M | — | — | — |
| 2024 | $0.00 | $-70.78M | — | — | — |
| 2025 | $0.00 | $-59.00M | — | — | — |
Frequently asked questions
What is Nautilus Biotechnology Inc's revenue?
Nautilus Biotechnology Inc's trailing twelve-month revenue is $190000.00. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How much free cash flow does NAUT generate?
NAUT produced $-51.97M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is NAUT's balance sheet healthy?
NAUT holds $12.39M in cash and equivalents against — in long-term debt, on $156.97M of shareholder equity. That debt is best read against the cash flow the business throws off each year.